Milurit (Allopurinol)

Allopurinol, the active ingredient in Milurit, is a xanthine oxidase inhibitor presented as an oral tablet for oral use. It reduces uric acid production and is employed in the management of gout, chronic hyperuricemia, and to prevent tumor lysis syndrome in patients undergoing chemotherapy.

GNH USA supplies Milurit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU‑derived quality standards and providing reliable global distribution. Our supply chain ensures product integrity from manufacture to end‑user.

Allopurinol is used in conditions where excess uric acid contributes to disease pathology. - Gout: lowers serum uric acid to reduce acute attacks and prevent chronic joint damage. - Hyperuricemia: maintains target uric acid levels to avoid crystal deposition and related complications. - Tumor lysis syndrome: prophylactically reduces uric acid surge during rapid cancer cell breakdown.

Allopurinol may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Rash: mild skin eruption that may appear shortly after therapy initiation. - Gastrointestinal discomfort: nausea, vomiting or abdominal pain. - Elevated liver enzymes: transient increase in hepatic transaminases. - Pruritus: itching without visible rash. - Diarrhea: loose stools. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe mucocutaneous reaction requiring immediate medical attention. - Toxic epidermal necrolysis: life‑threatening skin detachment. - Severe hypersensitivity syndrome: fever, eosinophilia, hepatitis, and renal impairment.

When prescribing Allopurinol, clinicians should consider several precautionary measures to minimise risk. - Renal function: dose may need adjustment in patients with impaired kidney function. - Hepatic impairment: monitor liver enzymes, especially during initiation. - Hypersensitivity history: avoid in individuals with prior severe reactions to allopurinol. - Concomitant azathioprine or 6‑mercaptopurine: increase risk of bone marrow suppression; monitor blood counts. - Cardiovascular disease: use cautiously in patients with ischemic heart disease due to rare reports of arrhythmias. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Allopurinol can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Azathioprine or 6‑mercaptopurine: increased myelosuppression; avoid co‑administration. - Warfarin: potentiates anticoagulant effect; monitor INR closely. - Zidovudine: may enhance toxicity; consider alternative antiretroviral.

Moderate Interactions (Monitor Closely): - Theophylline: reduced clearance leading to higher plasma levels; adjust dose if needed. - Amoxicillin/clavulanate: may increase risk of rash; observe for skin reactions. - Diuretics (e.g., thiazides): can raise serum uric acid; monitor uric acid levels.